231 S. Whisman Road
3 articles with SanBio
SanBio Company Limited announced it has concluded an agreement with Keio University School of Medicine on joint research for SB623 targeting dementia.
The Group hereby announces procurement of funds totaling ¥11,000 million upon completion of exercise of share acquisition rights with an exercise price adjustment clause issued on April 6, 2018.
SanBio's US-based Phase 1/2a Clinical Trial of SB623 for the Treatment of Chronic Motor Deficit from Ischemic Stroke Was Addressed at an Event Held by California Institute for Regenerative Medicine (CIRM)
The SanBio Groupn hereby announces that the US-based phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke